In brief aspirin duration following PCI for ACS, no harm occurs.

Published Date: 11 Nov 2023

In the T-PASS trial, less than a month of ticagrelor plus aspirin therapy, followed by ticagrelor alone for a year after PCI for ACS, was found to be noninferior to dual antiplatelet therapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot